Tenax Therapeutics with ticker code (TENX) now have 2 analysts in total covering the stock. The consensus rating is ‘None’. The target price ranges between 4 and 2 with a mean TP of 3. Now with the previous closing price of 1.03 this now indicates there is a potential upside of 191.3%. The 50 day moving average now sits at 1.05 and the 200 day MA is 1.21. The market capitalisation for the company is $14m. Visit the company website at: http://www.tenaxthera.com
Tenax Therapeutics, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing products for cardiovascular and pulmonary diseases in the United States and Canada. The company focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing low cardiac output syndrome. It is also involved in initiating a Phase 2 clinical trial of levosimendan for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction. The company was formerly known as Oxygen Biotherapeutics and changed its name to Tenax Therapeutics in September 2014. Tenax Therapeutics was founded in 1967 and is headquartered in Morrisville, North Carolina.